Rural America has millions of potential trial participants, but few sites to serve them. Rovia's CEO explains why finding and keeping the right principal investigators may be the real challenge, and what sponsors need to prove next.
- Why Radioligand Therapy Studies Look Nothing Like Standard Oncology Phase 1s
- Years Before Clinical Trials: The Decisions That Shape The Future Of Academic Cancer Discoveries
- Two Parallel Trials, A Potential New Option For Protection From COVID-19
- Firsthand Findings: How Incannex Is Designing Trials That Support Regulatory Approval
- The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
- Lupus Researchers Now Have A Three-Pillar RWD Platform To Support Discovery And Development
- Novel Science, Familiar Regulatory Pathways: Inside Tonix's Clinical Development Strategy
GUEST COLUMNISTS
-
Lupus Researchers Now Have A Three-Pillar RWD Platform To Support Discovery And Development
Lupus Nexus unites a registry, biorepository, and data exchange to give researchers longitudinal real-world data without building the infrastructure from scratch.
-
Novel Science, Familiar Regulatory Pathways: Inside Tonix's Clinical Development Strategy
Tonix CEO Seth Lederman, MD, explains how the company pairs novel science with proven regulatory paths across fibromyalgia, depression, and Lyme disease.
-
As U.S. Trial Share Slips, A Coalition Maps A Path To Broader Patient Access
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
A Window Into Aging: Why Skin Is the First Test For RLS-1496
Rubedo’s Marco Quarta explains how patient selection, controls, biopsies, and biomarkers shaped early RLS-1496 trial protocols.
-
Brazil's Regulatory Transformation: Building And Supporting Sites Beyond The AMCs
Our expert chat about Brazil’s clinical research transformation concludes with SBOC President-elect Fabio Franke, who explores building sustainable trial capacity beyond the country’s major AMCs.
-
Brazil's Regulatory Transformation: Expanding Clinical Trial Participation
A discussion of Brazil’s clinical research transformation continues as this Q&A series turns to Maiko L. Tonini, Ph.D., of Brazil’s Ministry of Health, to explore expanding clinical trial participation.
-
Brazil's Regulatory Transformation: A New Era For Clinical Development
Brazil’s clinical research transformation takes center stage as this new Q&A series opens with Interfarma CEO and former ANVISA director Renato Porto.
-
The Real Problem In Patient Recruitment… Is Knowing How And When To Use AI
AI might find patients faster, but only people earn their trust. A site COO explains how to pair AI speed with human judgment, plus the guardrails every site should build in.
CLINICAL TRIAL WHITE PAPERS
-
The Renaissance Of Psychedelic Research: History, Protocols, And Forward Trajectories
Discover how clinical trial protocols are evolving to address unblinding, therapeutic support variables, and regulatory standards in modern psychedelic research.
-
Optimizing Clinical Development Success In Hematologic Malignancies11/12/2026
From choosing the right endpoints to identifying eligible patients from a limited pool, see what it takes to move a new therapy for leukemia, lymphoma, or myeloma from early-stage studies to approval.
-
Navigating The Challenges Of Large, International Phase III Breast Cancer Trials5/27/2026
In the competitive landscape of breast cancer research, aligning biomarker testing, regulatory pathways, and regional operations from day one creates a path to faster enrollment and stronger outcomes.
-
5 Questions To Ask Before Selecting A Randomization Partner5/12/2026
Choose the right IRT partner for complex master protocols. Learn how adaptive randomisation expertise and flexible technology reduce disruption and keep trials execution-ready.
-
eSource Purpose Is Not Just To Complete The EDC7/7/2025
Central eSource transforms data capture from a passive, back-end chore into an active, real-time quality and compliance engine—delivering benefits that extend beyond faster EDC feeds and reduced SDV.
-
AI In Precision Medicine: Predictive Insight To Operational Confidence11/9/2026
Stop taking a reactive approach to trial delays. See how AI forecasting and connected lab and biomarker data help precision medicine teams spot problems sooner, with experts still making the calls.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
Supporting Global Approval Of A First-In-Class Gene Therapy For A Rare Genetic Disorder5/27/2026
Global approvals for a first-in-class gene therapy don’t happen by chance. See how adaptive oversight and inspection readiness kept a complex rare disease program moving forward.
-
How Cara Therapeutics Increased Compliance And Reduced Study Team Burden7/31/2025
Delve into the partnership that helped Cara Therapeutics achieve a significant milestone in their clinical research efforts to transform the lives of chronic pruritus patients.
-
Continuity And Risk Mitigation Following Unexpected QPPV Resignation5/26/2026
Rapid escalation and clear interim governance ensured compliance and operational continuity following an unexpected QPPV resignation, reducing inspection risk during a critical pharmacovigilance transition.
-
Expand Bandwidth With A Trusted Regulatory Writing Partner9/18/2025
Find out how a mid-size biotech lacking the bandwidth, expertise, and resources to independently handle its regulatory writing requirements overcame this challenge.
-
Tailored Approach Supports Bladder Cancer Breakthrough3/5/2026
Discover how a flexible operational strategy and expert site management help bladder cancer programs overcome complex logistical hurdles and achieve critical regulatory milestones.
-
Successful EU MAA Submission Enabled By U.S.–EU Regulatory Collaboration5/27/2026
Facing EU MAA complexity? Learn how one oncology sponsor met a fixed EMA deadline through global regulatory coordination, rapid dossier adaptation, and real-time submission execution.
NEWSLETTER ARCHIVE
- 11.17.26 -- From Consent To TMF: Tech Built Around The Realities Of Site Work
- 11.16.26 -- Care Gaps, Dropout, And Data Variability: Where Trials Quietly Break Down
- 11.14.26 -- Best Of October
- 11.13.26 -- Fewer Data Silos, Sharper Dose Decisions, Shared Site Intel: What Trial Teams Want Now
- 11.13.26 -- Partnering Across The Pipeline: Early Oncology To Ultra-Rare Approvals
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
Recruitment problems can start long before actual recruitment. Who is making sure your team gets ahead of those challenges?
-
Lupus Nexus unites a registry, biorepository, and data exchange to give researchers longitudinal real-world data without building the infrastructure from scratch.
-
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
FOCUS ON PATIENTS
-
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
Clinical trial patients may need care outside of the trial protocol. Discover how closing information gaps can protect safety, trial participation, and data integrity.
-
Can early APG-157 treatment control head and neck cancer without delaying curative care? A Phase 3 trial puts timing, safety, and outcomes to the test.
EDITORIAL COLLECTIONS
Take a deep dive into the issues shaping clinical research today with our curated Editorial Collections. Each collection features expert insights and practical strategies addressing today’s biggest challenges in clinical trial planning and execution.
More Editorial Collections
